

DECLARATION AND POWER OF ATTORNEY

As the below-named inventors, we declare that:

Our residences, post office addresses, and citizenships are as stated below under our names.

We have reviewed and understand the contents of the foregoing specification, including the claims, and we believe we are the original, first and joint inventors invention entitled "METHODS OF PRODUCING SECRETED RECEPTOR ANALOGS _AND BIOLOGICALLY ACTIVE DIMERIZED - POLYPEPTIDE FUSIONS," which is described and claimed in the specification and claims of patent application Serial No. 07/634,510, which we filed in the United States Patent and Trademark Office on December 27, 1990 (hereinafter referred to as "later C-I-P application"); and that this application in part discloses and claims subject matter disclosed in our earlier filed pending application entitled "METHODS OF PRODUCING SECRETED RECEPTOR ANALOGS AND BIOLOGICALLY ACTIVE PEPTIDE DIMERS," Serial No. 07/347,291, filed May 2, 1989 (hereinafter referred to as "earlier application").

We hereby claim priority based on a foreign patent application filed in Europe on January 18, 1989, identified by Application No. 89100787.4

We acknowledge our duty to disclose information of which we are aware which is material to the examination of this application in accordance with 37 C.F.R. § 1.56(a), including material information which occurred between the filing date of said earlier filed pending application and the present.

We hereby appoint RICHARD W. SEED, Registration No. 16,557; ROBERT J. BAYNHAM, Registration No. 22,846; EDWARD W. BULCHIS, Registration No. 26,847; GEORGE C. RONDEAU, JR., Registration No. 28,893; DAVID H. DEITS, Registration No. 28,066; WILLIAM O. FERRON, JR., Registration No. 30,633; PAUL T. MEIKLEJOHN, Registration No. 26,569; DAVID J. MAKI, Registration No. 31,392; MICHAEL J. FOLISE, Registration No. 31,952; ROBERT M. STORWICK, Registration No. 30,112; RICHARD G. SHARKEY, Registration No. 32,629; GEORGE B. FOX,

Registration No. 31,510; DAVID V. CARLSON, Registration No. 31,153; MAURICE J. PIRIO, Registration No. 33,273; KARL R. HERMANNS, Registration No. 33,507; L. GRANT FOSTER. Registration No. 33,236; DAVID D. McMASTERS, Registration No. 33,963; and JOHN M. KELLY, Registration No. 33,920, composing the firm of SEED and BERRY, 6300 Columbia Center, Seattle, Washington 98104-7092, our attorneys to prosecute this application and transact all business in the Patent Trademark Office connected therewith. Please direct all telephone calls to David J. Maki at (206) 622-4900 and telecopies to (206) 682-6031.

We further declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that the making of willfully false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and may jeopardize the validity of any patent issuing from this patent application.

Andrzej Z. Sledziewski

Date 03/01/91

Residence : City of Seattle, County of King

State of Washington

Citizenship : Poland

P.O. Address: 14543 - 30th Avenue N.E.

Seattle, Washington 98155

2-24-98 :11:34AM :

2066236783→

Date Fib 6, 1991

Residence

City of Seattle, County of King

State of Washington

Citizenship : United States of America

P.O. Address : 7545 - 12th N.W. Avenue

Seattle, Washington 98117

Residenće

City of Seattle, County of King

State of Washington

Citizenship : United States of America

P.O. Address : 6014 - 24th Avenue N.E.

Seattle, Washington 98115



Applicants

Andrzej Z. Sledziewski, Lillian A. Bell, Wayne R. Kindsvogel

Serial No.

08/477,329

Filed

June 7, 1995

For

METHODS OF PRODUCING SECRETED RECEPTOR ANALOGS

AND BIOLOGICALLY ACTIVE DIMERIZED POLYPEPTIDE FUSIONS

Examiner

Art Unit

1805

Docket

ZY1.P10C6

Assistant Commissioner of Patents

Washington, D.C. 20231

SUBSTITUTE POWER OF ATTORNEY

Sir:

I, Mark J. Murray, Vice President, Business Development of ZymoGenetics, Inc., a corporation of the State of Washington, having a place of business at 1201 Eastlake Avenue East, Seattle, WA 98102, hereby declare that ZymoGenetics, Inc. is the assignee of the above-identified application, which is a continuation of Serial No. 08/180,195, filed January 11, 1994, which is a continuation of Serial No. 07/634,510, filed December 27, 1990, which is a continuation in part of Serial No. 07/347,291, filed May 2, 1989 (U.S. Patent No. 5,155,027), which is a continuation in part of Serial No. 07/146,877, filed January 22, 1988. Documentary evidence of chain of title from the original owners to ZymoGenetics, Inc. has been filed with the United States patent and Trademark Office and has been recorded at Reel 5630, Frame 0638. I have reviewed the evidentiary documents referred to herein and it is certified that, to the best of my knowledge and belief, title is in ZymoGenetics, Inc.

ZymoGenetics, Inc., assignee of the entire interest in the above-mentioned application, hereby revokes all powers of attorney heretofore given in the above-referenced application and hereby appoints JEFFREY J. KING, Reg. No. 38,515; FRANK ABRAMONTE, Reg. No. 38,066; CHRIS E. SVENDSEN, Reg. No. 40,193; BETH A HAGEN, Reg. No. 37,032; and GEORGE A. CASHMAN, Reg. No. 26, 448, as the principal attorneys with full power of substitution, association and revocation to transact all business in

the Patent and Trademark Office connected therewith, and to all notices relating to the prosecution and issuance of this application. Please direct all future correspondence to:

Jeffrey J. King STRATTON BALLEW PLLC 1218 Third Avenue, Suite 1313 Seattle, Washington 98101

and direct all telephone calls to Jeffrey J. King at (206) 682-1496 or facsimiles to (206) 682-0446.

Please change the attorney docket number to ZY1.P10C6.

I further represent that I have the authority to execute this document on behalf of ZymoGenetics, Inc. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that the making of willfully false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and may jeopardize the validity of any patent issuing from this patent application.

7-15-46

Date

Mark J. Murray, Ph.D.

Vice President, Business Development

Client No.: 87-19C4